A setting of small-cell lung cancer (SCLC) that has not seen its standard-of-care treatment change since the 1980s is poised to enter the immunotherapy era based on positive results from a study using AstraZeneca PLC’s PD-L1 inhibitor Imfinzi (durvalumab). But while it marks a major advance, the track record of adding AstraZeneca’s CTLA-4 inhibitor Imjudo (tremelimumab-actl) has not shown the same level of success.
ASCO: AstraZeneca’s ADRIATIC Passes One Test, With One More To Go
The results for Imfinzi mark the first significant advance in LS-SCLC in four decades, but will the combination with Imjudo succeed after flopping in CASPIAN?
More from ASCO
• By
Iovance’s Amtagvi won FDA accelerated approval in February, and Adaptimmune’s afami-cel may not be far behind, but cell therapies for solid tumors come with some extra challenges.
• By
The discussant at ASCO’s NSCLC session said the field would need to “manage expectations” as the drugs do not appear to beat chemotherapy in all-comers.
• By
Scrip reporter Alaric DeArment is joined by the Datamonitor Healthcare oncology analysts to review key highlights from the recent American Society of Clinical Oncology annual meeting.
• By
US-based Citeline writer Sarah Karlin-Smith joins Brian Yang and Dexter Yan in China to discuss the US BIOSECURE Act and the recent BIO meeting in San Diego, while Dexter Yan discusses China-related ASCO highlights, in this mixed Chinese- and English-language episode.
More from Conferences
• By
All the elements for a big M&A year are in place, but political uncertainty and interest rates could push more deals into the second half of the year, according to business development experts at BIO CEO & Investor.
• By
Highlights from the BIO CEO & Investor Conference, held in New York 10-11 February, include the impact of US political changes, Chinese companies entering the obesity race, and IPO pitfalls.
• By
Bristol Myers Squibb has been in a rapid growth phase to make up for upcoming losses of exclusivity. Scrip spoke with executives about further catalysts coming in the next 18-24 months.